ACE inhibitor lacks acute effect on cognition or brain blood flow in alzheimer's disease

Myron F. Weiner, Frederick J. Bonte, Ron Tintner, Neville Ford, Doris Svetlik, Teresa Riall

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

The effects of the acute administration of the ACE inhibitor ceronapril were studied in 12 Alzheimer's disease (AD) patients and 2 age-matched controls. A 4-week open trial was performed with daily doses of 40-80 mg/day. Testing was performed at baseline and at 4 weeks using the Mini-mental State Exam and the cognitive portion of the Alzheimer's Disease Assessment Scale as cognitive measures, and regional cerebral blood flow (rCBF) as determined by Xe 133 single-photon emission computerized tomography as an indirect measure of brain metabolism. There was no effect on cognition and blood flow increased significantly only in the left temporal region. It was concluded that the acute administration of the ACE inhibitor ceronapril had no significant acute effect on cognitive function or rCBF in AD.

Original languageEnglish (US)
Pages (from-to)467-471
Number of pages5
JournalDrug Development Research
Volume26
Issue number4
DOIs
StatePublished - Jan 1 1992

Keywords

  • ceronapril
  • dementia
  • rCBF

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'ACE inhibitor lacks acute effect on cognition or brain blood flow in alzheimer's disease'. Together they form a unique fingerprint.

Cite this